196 related articles for article (PubMed ID: 23759318)
1. Immune status following alemtuzumab treatment in human CD52 transgenic mice.
Turner MJ; Lamorte MJ; Chretien N; Havari E; Roberts BL; Kaplan JM; Siders WM
J Neuroimmunol; 2013 Aug; 261(1-2):29-36. PubMed ID: 23759318
[TBL] [Abstract][Full Text] [Related]
2. Depletion of CD52-positive cells inhibits the development of central nervous system autoimmune disease, but deletes an immune-tolerance promoting CD8 T-cell population. Implications for secondary autoimmunity of alemtuzumab in multiple sclerosis.
von Kutzleben S; Pryce G; Giovannoni G; Baker D
Immunology; 2017 Apr; 150(4):444-455. PubMed ID: 27925187
[TBL] [Abstract][Full Text] [Related]
3. Differential reconstitution of T cell subsets following immunodepleting treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with relapsing-remitting multiple sclerosis.
Zhang X; Tao Y; Chopra M; Ahn M; Marcus KL; Choudhary N; Zhu H; Markovic-Plese S
J Immunol; 2013 Dec; 191(12):5867-74. PubMed ID: 24198283
[TBL] [Abstract][Full Text] [Related]
4. In vitro and in vivo evaluation of direct rhenium-188-labeled anti-CD52 monoclonal antibody alemtuzumab for radioimmunotherapy of B-cell chronic lymphocytic leukemia.
De Decker M; Bacher K; Thierens H; Slegers G; Dierckx RA; De Vos F
Nucl Med Biol; 2008 Jul; 35(5):599-604. PubMed ID: 18589304
[TBL] [Abstract][Full Text] [Related]
5. CD52 is expressed on human mast cells and is a potential therapeutic target in Waldenstrom's Macroglobulinemia and mast cell disorders.
Santos DD; Hatjiharissi E; Tournilhac O; Chemaly MZ; Leleu X; Xu L; Patterson C; Branagan AR; Manning RJ; Ho AW; Hunter ZR; Dimmock EA; Kutok JL; Churchill WH; Castells MC; Tai YT; Anderson KC; Treon SP
Clin Lymphoma Myeloma; 2006 May; 6(6):478-83. PubMed ID: 16796779
[TBL] [Abstract][Full Text] [Related]
6. [Alemtuzumab, a monoclonal antibody against CD52: hopes and fears].
Mori M
Brain Nerve; 2014 Oct; 66(10):1179-89. PubMed ID: 25296872
[TBL] [Abstract][Full Text] [Related]
7. Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model.
Hu Y; Turner MJ; Shields J; Gale MS; Hutto E; Roberts BL; Siders WM; Kaplan JM
Immunology; 2009 Oct; 128(2):260-70. PubMed ID: 19740383
[TBL] [Abstract][Full Text] [Related]
8. Expression of CD52 in peripheral T-cell lymphoma.
Piccaluga PP; Agostinelli C; Righi S; Zinzani PL; Pileri SA
Haematologica; 2007 Apr; 92(4):566-7. PubMed ID: 17488672
[TBL] [Abstract][Full Text] [Related]
9. Alemtuzumab (Compath) off-label for relapsing multiple sclerosis.
Med Lett Drugs Ther; 2009 Mar; 51(1307):17-8. PubMed ID: 19265776
[No Abstract] [Full Text] [Related]
10. A novel Raji-Burkitt's lymphoma model for preclinical and mechanistic evaluation of CD52-targeted immunotherapeutic agents.
Lapalombella R; Zhao X; Triantafillou G; Yu B; Jin Y; Lozanski G; Cheney C; Heerema N; Jarjoura D; Lehman A; Lee LJ; Marcucci G; Lee RJ; Caligiuri MA; Muthusamy N; Byrd JC
Clin Cancer Res; 2008 Jan; 14(2):569-78. PubMed ID: 18223233
[TBL] [Abstract][Full Text] [Related]
11. Activity of alemtuzumab in patients with CD52-positive acute leukemia.
Tibes R; Keating MJ; Ferrajoli A; Wierda W; Ravandi F; Garcia-Manero G; O'Brien S; Cortes J; Verstovsek S; Browning ML; Faderl S
Cancer; 2006 Jun; 106(12):2645-51. PubMed ID: 16688777
[TBL] [Abstract][Full Text] [Related]
12. Characterisation of a Novel Anti-CD52 Antibody with Improved Efficacy and Reduced Immunogenicity.
Holgate RG; Weldon R; Jones TD; Baker MP
PLoS One; 2015; 10(9):e0138123. PubMed ID: 26372145
[TBL] [Abstract][Full Text] [Related]
13. Impact of antimouse CD52 monoclonal antibody on graft's γδ intraepithelial lymphocytes after orthotopic small bowel transplantation in mice.
Shen B; Yu H; Hao X; Qu L; Cai X; Li N
Transplantation; 2013 Mar; 95(5):663-70. PubMed ID: 23503501
[TBL] [Abstract][Full Text] [Related]
14. Effect of alemtuzumab on neoplastic B cells.
Golay J; Manganini M; Rambaldi A; Introna M
Haematologica; 2004 Dec; 89(12):1476-83. PubMed ID: 15590398
[TBL] [Abstract][Full Text] [Related]
15. CD52 expression patterns in myeloma and the applicability of alemtuzumab therapy.
Rawstron AC; Laycock-Brown G; Hale G; Davies FE; Morgan GJ; Child JA; Hillmen P; Owen RG
Haematologica; 2006 Nov; 91(11):1577-8. PubMed ID: 17043027
[TBL] [Abstract][Full Text] [Related]
16. Human peripheral blood mononuclear cells exhibit heterogeneous CD52 expression levels and show differential sensitivity to alemtuzumab mediated cytolysis.
Rao SP; Sancho J; Campos-Rivera J; Boutin PM; Severy PB; Weeden T; Shankara S; Roberts BL; Kaplan JM
PLoS One; 2012; 7(6):e39416. PubMed ID: 22761788
[TBL] [Abstract][Full Text] [Related]
17. Effect of anti-CD52 antibody alemtuzumab on ex-vivo culture of umbilical cord blood stem cells.
Lim CK; Sun L; Feng Q; Law P; Chua WT; Lim SN; Hwang WY
J Hematol Oncol; 2008 Oct; 1():19. PubMed ID: 18947412
[TBL] [Abstract][Full Text] [Related]
18. CD52-Negative NK Cells Are Abundant in the Liver and Less Susceptible to Alemtuzumab Treatment.
Hotta R; Ohira M; Matsuura T; Muraoka I; Tryphonopoulos P; Fan J; Tekin A; Selvaggi G; Levi D; Ruiz P; Ricordi C; Vianna R; Ohdan H; Waldmann H; Tzakis AG; Nishida S
PLoS One; 2016; 11(8):e0161618. PubMed ID: 27560943
[TBL] [Abstract][Full Text] [Related]
19. Anti-CD52 antibody, alemtuzumab, binds to Langerhans cells in Langerhans cell histiocytosis.
Jordan MB; McClain KL; Yan X; Hicks J; Jaffe R
Pediatr Blood Cancer; 2005 Mar; 44(3):251-4. PubMed ID: 15390358
[TBL] [Abstract][Full Text] [Related]
20. CD52 antigen expressed by malignant plasma cells can be targeted by alemtuzumab in vivo in NOD/SCID mice.
Carlo-Stella C; Guidetti A; Di Nicola M; Longoni P; Cleris L; Lavazza C; Milanesi M; Milani R; Carrabba M; Farina L; Formelli F; Gianni AM; Corradini P
Exp Hematol; 2006 Jun; 34(6):721-7. PubMed ID: 16728276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
